¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º GwVSRI:[N  
76*5/J-  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ ! =c&U.B  
KI Ua  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) (Sg52zv  
$r=Ud >  
1. ICAM-1 d6k`=Hlg  
G?6[K&w  
2. interleukin 12(IL-12) ojH-;|f  
i;>Hy|  
3. tumor infiltrating lymphocyte .sDVBT'%  
3E361?ubM  
4. TCR/CD3 complex x~tG[Y2F?  
k iCg+@nT  
5. hematopoietin receptor family LJMw-#61sj  
1vQj` F  
6. individual idiotype(IdI) vx_v/pD  
RSY{IY  
7. integrin JtU/%s  
F+S;u=CKx  
8. colony-stimulatory factor (CSF) ukr a)>Y[|  
pr[[)[]/  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© M+ gYKPP  
}cE,&n  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? *r+i=i8{  
|T9p#) ec2  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ xF_ Y7rw1w  
3L4lk8Dd  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ6;GL> ))'  
@qH<4`y.^  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ xgtdmv%  
^6ZA2-f/<8  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) rj*4ZA ?  
?iUAzM8  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ %?C{0(Z{  
JF_\A)<ki  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) <vA^%D<\~  
lB L;aTzo  
3. immunoglobulin superfamily (IgSF) 1z$;>+g<  
rBkf@  
4. selectin lyx p:  
V D.p"F(]  
5. anti-idiotypic antibody (¦ÁId) q0w5ADd  
%"DEgI P  
6. major histocompatibility complex(MHC) zie])_8|h  
NJ 7N*   
7. immunotolerance 2[Q*?N  
>u~ [{(d ,  
8. biological reponse modifier(BRM) rGRxofi.  
wr8n*Du  
9. immune reponse gene (Ir gene) (ZjIwA9>  
F1)Q#ThF\  
10. reshaped antibody (or reconstituted antibody) Sy'/%[+goJ  
E[6JHBE*r  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© dt) BMF8  
b2H!{a"  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ }vxb, [#  
7|T5N[3?l,  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? m^O:k"+!  
r[ ' T.yo  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ ay'= M`uO_  
Rmn|"ZK  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? W2yNEiH  
"(/|[7D)  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ c$?qN&X_K  
nPfVZGt  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? u-pE ;|  
|>A1J:  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ @*q\$Eg}2  
c"H4/,F  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ *A GC[w}/  
E[nWB"pxE  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? =a?l@dI]  
|vTirZP  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ p."pI Bd  
T {(6*^g<B  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: qp  
/.$ n>:XR  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 0$}+t q+  
*u 3K8"XZ  
ÃâÒßѧ 5^GUuFt5m  
U&w Ve$  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ;r^8In@6  
\ zhT1#O  
1. CD8 x~j%  
I@+dE V`Lf  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) &UbNp8h  
+X cB5S>  
3. immunoglobulin fold(Ig fold) K}`.?6O  
G:c)e ,pD  
4. cadherin (Ca-dependent cell adhesion moleculers) b&HA_G4  
2Ev~[Hb.  
5. idiotype-anti-idiotypic antibody immune network theory %Ni)^   
9d#-;qV  
6. HLA class II antigen -AD3Pd|Y[  
=6ZZ/+6b  
7. complementarity-determining region (CDR) 'Xxt[Jy  
KNQX\-=  
8. perforin(or pore-forming protein ,PFP) r<UZ\d -  
5z5#_*)O  
9. high affinity IL-2 receptor y''`73U"  
jNaK]  
10. artificial active immunization db@i*Bf  
.N5}JUj  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,Tvk&<!0  
w%S\)wjS  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ>y(;k|-$  
&]ts*qCEL  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 &Jk0SUk MP  
] 8+!  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ vCFMO3  
 J5*krH2i  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ :JV= Kt  
t*NZ@)>  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ J)x-Yhe  
A'c0zWV2  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ?y>P  
q}*(rR9/Br  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ )c^Rc9e/  
\v)Dy)Vhg2  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 3 i Id>  
"|{ NRIE  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Yev] Lp  
T4]/w|?G  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ONH!ms(kb  
)^qM%k8  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 9y{[@KG  
F=7X,hK  
1. immunoglobulin gene rearrangement MCZTeYnx  
Q>8F&p?R  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) GbUw:I  
)e d5~ok  
3. flow cytometry(FCM) v8Vw.Ce`f  
9]<p  
4. carrier effect >v7fR<(%s  
Hbu8gqu  
5. positive selection of T lymphocytes in thymus 2&MIt(\-  
##+|zka!U  
6. mouse TH1(Th1) and TH2(Th2) subsets VG0Ty;bV  
~b}a|K  
7. perforin (pore-forming protein ,PFP) |5oK04<  
'3TwrY?-  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) /j/,@,lw7z  
JL[$B1  
9. SH-2(src-homology region 2) %sxLxx_x!  
Jmrs@  
10. Ab2¦Â (internal image) 3#N'nhUzA  
r<VZE bm)  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© nGQc;p5;  
%IrR+f+H  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? i[_ (0P+Da  
5 .m&93P  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? vT/e&8w  
.c__<I<G<  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠtpu2e*n-|  
G"k.sRKu  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ?YE'J~0A6  
v: \8  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ<A|X4;  
w-iu/|}  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) `wI$  
8^IV`P~2M  
ÃâÒßѧרҵ£º Sg%h}]~   
EdL2t``  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ / esdtH$=  
LTZ8Eu  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 6jw9p+.  
$>JfLSyC  
´«È¾²¡Ñ§×¨Òµ£º uzoI*aqk-s  
Ky0}phGRu  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 3Pu8IXW  
e{Q;,jsh  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ q t(+X  
mXYG^}  
Ïû»¯×¨Òµ£º ,`Keqfx  
kzE<Y  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ` 0$i^,}  
qX[{_$^Q  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? zG0]!A  
gt(^9t;  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ [vGkr" =  
u^O!5 'D%  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 3F?7oMNIh  
I4|LD/b  
1. Fas(CD95)/FasL aD(3.=[R  
bm*.*A]  
2. common chain of cytokine receptor oVTXn=cYDp  
yhkKakg,)  
3 . TCR/CD3 complex 7lx" X0w*m  
hgj ]Jr  
4. negaive selection of thymocytes UX2@eyejQ7  
S:K$fFcJ  
5. artificial active immune s TVX/Q  
qeW.~B!B  
6. anti-idiotypic eZ oAy[  
4]HW!J  
7. IgSF p,V%wG M  
zcC:b4  
8. Integrin 4(91T  
NEUr w/  
9. chemokine 2,Aw 6h;  
Q #X'.](1  
10. B7/CD28 xk  
S0Ur{!9\#^  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© -e_|^T"  
oiIl\#C  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ ny%$BQM=  
;"2VU"  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ ]WzeJ"r {3  
joDqv,iW8  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ .p]r S =#  
#K`0b$  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ r7sA;Y\  
M KX+'p\w  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ s q;!5qK  
ie11syhV"  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ l[]cUE  
+?W4ac1  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 2~ 4&4  
mlCBstt{  
1. B7/CD28 d``wx}#Uk  
6uv~.-T<l  
2. Th1 subset L+VQtp &"  
 s_}6#;  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© >&Oql9_  
Vhh=GJ  
4. antibody affinity maturation #s81 k@#X  
,NvXpN  
5. AP-1 .heU Ir,  
gq;>DY]   
6. single chain variable fragment£¨ScFv£© o<iU;15  
J^ewG  
7. NK cell receptor ]jm:VF]4  
utBrH  
8. Zinkernagel-Doherty phenomenon b1cVAfUP  
4x q|  
9. Ig fold ^e <E/j{~  
[>r0 (x&.  
10. CD40/CD40L \>pm (gF  
v*qbzW`  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© '8\9@wzv  
[` qdpzUp&  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ X[r0$yuE  
@y~kQ5k  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ YI;iG[T,&  
aA52Li  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ J{prI;] K  
|%F,n2  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ (DY[OIHI  
\.O&-oi  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ /z4c>)fV  
0"% dPKi  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ @`C'tfG /4  
DE/SIy?  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ^}p##7t [  
WEe7\bWF  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©  jF0"AA  
`MuX/ [q  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© _Iav2= 0Wi  
|r Aot2  
1.Co-stimulators (or co-stimulating molecules) !|xB>d q?  
f+uyO7  
2.NK-kB  *0^~@ U  
(~zu4^9w  
3.Immunoglobulin superfamily f%@~|:G:  
=FhP$r*  
4.antigen-presenting cell (APC) jL^@;"/XhC  
Wy7w zt  
5.death domain JOY&YA$U  
Oa~ThbX7  
6.CCR and CXCR N=<`|I  
oC>J{z  
7.Lectin (or mitogen) X'PZCg W  
d7vPZ_j^z  
8.Clusters of differentiation, CD) W<pr Y  
F6[F~^9D  
9.B7 family MmjZq  
F5 ]<=i  
10.Cytotoxic T lymphocyte, CTL) jjj<B'zt  
{V QGfN  
11.IL-15 and IL-15 receptor (IL-15R) 6[ A\cs  
T \}U{9ELL  
12.MHC restriction vw2E$ya  
3?*d v14  
13.Affinity-chromatography 05FGfnq.8  
r$={_M$  
14.Cyctosprin A, CsA AuXUD9 -  
H1kI+YJ@  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ,w#lUg p  
R|\eBnfI  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© H:~p5t  
1PwtzH .w  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 nd8<*ru$  
_:m70%i  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ _R ii19k  
\ =hg^j  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ pKc!sd C  
kuH%aM<R  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© dP8qP_77A~  
]AY 4bm  
ÃâÒßѧרҵ£º ..8t1+S6]  
kS-BB[T  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ w"9h_;'C_  
{S=<(A @  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ m0bxVV^DK!  
plWN uEW  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ .jQx2 O  
MeBTc&S<  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ)  ImhkU%  
Z3TCi7,m  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) #g6_)B=S  
fF0K].  
1. ADCC(antibody dependent cell-mediated cytotoxicity) $ Lstq_x+  
YdCl  
2. »·æß¾úËØ(cyclosporin) ExO#V9DaW  
<9pI~\@w  
3. KIR(killer cell inhibitory receptor) vX }iA|`#  
@sn:%/x_  
4. HLDA(human leucocyte differentiation antigen) `?$-T5Rr  
AJ/Hw>>$?m  
5. Interleukin 18(IL-18) En&7e  
K7&]| ^M9  
6. ÕûºÏËØ(integrin) l5w^rj  
9\!&c<i=  
7. Fas/FasL OG<*&V  
\ *CXXp`  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) )$^xbC#j`3  
-`q!mdA2  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) l)$mpMgAD  
h's[) t  
10. Th1/Th2 =M 8Mt/P  
Q)aoc.f!v  
11. »ùÒòÒßÃç(DNAÒßÃç) vltE2mb  
+iN!$zF5]  
12. chemokines and chemokine receptor 9'p| [?]v  
LeN }Q  
13. ÃâÒßÄÍÊÜ nycJZ}f:wP  
AT t.}-  
14. ¹²´Ì¼¤·Ö×Ó %GjG.11V,_  
9Y2u/|!.3  
15. ËÀÍö½á¹¹Óò(death domain) $!G|+OuTR  
!"phz&E5ah  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) ){GJgk|P  
rs4:jS$)  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? # d"M(nt  
`ci  P  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠsuQ`a_ zJ  
L ' _%zO  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î %zc.b  
7y&=YCkc7  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ 2 O(k@M5E?  
b^[>\s'  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå )`k+Oyvi<  
aU +uPP  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ eiOAbO#U  
:zC=JvKT  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) &VjPdu57  
cJT_Qfxx  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ h Q Att  
d?U ,}tv  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ pkIQ,W{Ke  
eG1A7n'6W  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»